cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6073/pasta/f3f36c8180ba4bd1f830422f05c2b2ac
title: GOES-R Land Surface Products at AmeriFlux and NEON, Inc. Eddy Covariance Tower Locations

description: The terrestrial carbon cycle varies dynamically over short periods that can be difficult to observe. Geostationary (“weather”) satellites like the Geostationary Operational Environmental Satellite - R Series (GOES-R) deliver near-hemispheric imagery at a ten-minute cadence, and its Advanced Baseline Imager (ABI) measures visible and near-infrared spectral bands that can be used to estimate land surface properties and carbon dioxide flux. GOES-R data are designed for real-time dissemination and are difficult to link with eddy covariance time series of land-atmosphere carbon dioxide exchange. We compiled three-year time series of GOES-R land surface attributes including visible and near-infrared reflectances, land surface temperature, and downwelling shortwave radiation (DSR) at 318 ABI fixed grid pixels containing eddy covariance towers for years 2020-2022. We demonstrate how to best combine satellite and in-situ datasets, and show how ABI attributes useful for carbon cycle science vary across space and time. By connecting observation networks that infer rapid changes to the carbon cycle, we can gain a richer understanding of the processes that control it.
DOI: 10.6084/m9.figshare.24239305
title: shap_values.pkl

description: SHAP values for phase predictor
DOI: 10.6084/m9.figshare.24239305.v1
title: shap_values.pkl

description: SHAP values for phase predictor
DOI: 10.25345/c5j09wf6c
title: MassIVE MSV000093022 - In vivo protein synthesis in synapses is robust and disrupted early in dementia models
title: To understand synaptic dysfunction underlying dementias, we analyzed the synaptic proteome in mice using unbiased proteomics and in vivo pulse labeling of proteins in hippocampus with L-Azidohomoalanine. We identified an unexpected large-scale capability for protein biosynthesis within synapses and established local synthesis of 360 proteins, most mediating rapid responses (eg. synaptic transmission and endocytosis). These were functionally distinguishable from proteins delivered primarily by axonal transport, which included core translation machinery and ribonucleoprotein (RNP) granules. Mouse dementia models expressing either wildtype hAPP, hTauP301S, or hTDP43A315T exhibited deficiencies of locally synthesized proteins at early disease stages associated with selective depletion of protein translation machinery including RNP granule components. Our comprehensive multi-omic synaptic database reveals a previously under-appreciated elaborate satellite for local protein biosynthesis. Early deficiencies in translation capacity in three genetic neurodegenerative models with impaired memory suggest a shared contribution to cognitive decline in dementias.
DOI: 10.25934/00004116
title: Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and individual patient data network meta-analysis

description: Alzheimer's dementia (AD) is the most common cause of dementia, and has an insidious onset with progressive deterioration in cognition (eg, memory, thinking and perception), function, behaviour and mood. To date, 46.8 million people worldwide live with dementia. This number will almost double every 20 years, and it is estimated to reach 131.5 million by 2050.[1] A study showed that as age increases, the rates of AD increase overall for both men and women, but it is more prevalent in women (rate/100 years=2.50 (1.85–3.41)) than men (rate/100 years=1.89 (1.22–2.94)).[2] It is currently unclear if galantamine, rivastigmine or donepezil should be used by patients with severe AD, and whether memantine is the most optimal treatment for severe AD.[3] The use of acetylcholinesterase inhibitors and increased doses of donepezil in patients with dementia increase the risk of bradycardia, as well, cholinesterase inhibitors doubles the risk of hospitalisation for bradycardia in older patients.[4, 5] Also, the use of other medications may increase risk of adverse events. For example, cardiac medications like β-blockers may increase risk of bradycardia, and anti-inflammatories may increase risk for gastrointestinal bleeding.[4, 6-8]

We previously attempted a systematic review and NMA of aggregated data, but we were unable to provide definitive conclusions regarding the influence of patient characteristics on the results.[9, 10] In this study we tailored results to age, AD severity, comorbidity and study duration via subgroup analysis. These results were similar to 4 Cochrane reviews examining cognitive enhancers for AD.[11-14] Specifically, the reviews showed that donepezil, rivastigmine and galantamine, significantly improved cognition[11-14] against placebo, yet cholinisterase inhibitors overall and donepezil improved behaviour,[11, 12]cholinisterase inhibitors overall and rivastigmine improved function,[12, 13] and rivastigmine improved AD severity.[13] These effects were associated with higher doses of rivastigmine,[13] suggesting that dose may be a treatment effect modifier. The use of IPD will increase power and will help explain the relationship between treatment effects and patient-level characteristics.
DOI: 10.6084/m9.figshare.24239353
title: Fig1 iEP data subset

description: Anndata object for reproducing some of the plots in Fig. 1 of the CellTag-multi 2023 paper: 210913_iep_rep_b4/fig1_subset_data_analysis/<br><br>Code for reproducing major plots and analyses can be found here: https://github.com/morris-lab/CellTag-multi-2023/tree/main
DOI: 10.25934/00004117
title: Predictors of Treatment Response, Adverse Events, Changes in Anaemia status and Assessment of Lesion Count Variability in Hidradenitis Suppurativa

description: Hidradenitis Suppurativa (HS) is a chronic inflammatory disease affecting between 1%-4% of the general population. It has a propensity to affect women and causes painful, chronically draining abscesses, nodules and tunnels in the axillae, groin and other flexural areas. There is a limited understanding of the disease, particularly factors that influence successful (or unsuccessful) treatment of the disease with current therapies.
Our project contains a number of sub-studies which will aim to further investigate contributing factors associated with Adalimumab (Humira) therapy, as well as factors related to assessment of disease, which plays an important role in how the disease is assessed in future clinical trials. 

These separate projects are all of high interest to clinicians treating Hidradenitis Suppurativa (HS) as well as researchers investigating the disease. The separate projects are as follows:

1) Rates of Malignancy and Serious Infections in Hidradenitis Suppurativa Patients Treated with Adalimumab
2) Predictors of Loss of Treatment Response in Patients with Hidradenitis Suppurativa treated with Adalimumab
3) The effect of Body weight upon clinical response rates in patients with Hidradenitis Suppurativa treated with Adalimumab
4) The effect of Adalimumab therapy in Hidradenitis Suppurativa upon anemia of chronic disease
5) Assessing the normal variability of lesion counts and disease activity in Hidradenitis Suppurativa.

Each of these 5 sub-studies addresses important, as yet poorly defined aspects of the disease and treatment with Adalimumab. Increasing our knowledge in these areas will help optimize treatment outcomes for patients, understand the effect of treatment upon patient outcomes and increase patient compliance, satisfaction and quality of life.
DOI: 10.25934/00004316
title: Geospatial and Seasonal Variation in Psoriasis Severity:  Analysis of Placebo Response Data from Phase 3 placebo-controlled trials in moderate-severe psoriasis

description: In placebo controlled randomized clinical trials of new therapeutics for moderate to severe psoriasis patients, some patients assigned to the placebo arm experience clinical improvement in their psoriasis signs.  The basis for this observed improvement is not clear.  Possible explanations include: random fluctuations in disease severity, increased attention to skin care instigated by study personnel translating into more diligent application of emollients by the subject, or the subject experiencing the psychological benefit of inaccurately believing that he or she is receiving effective experimental therapy (i.e., the true “placebo” effect).  In addition to these explanations, it is also possible that seasonal fluctuations in ambient UV exposure may account for some of the response observed among placebo patients.  The purpose of the proposed research is to investigate if and to what extent fluctuations in ambient UV exposure could be causing improvements in psoriasis among patients being treated with placebo.

There is evidence from the dermatologic literature for seasonal variation in psoriasis severity:  Pascoe and Kimball (2015) collected psoriasis PGA (Physician's Global Assessment) scores from psoriasis patients in a large New England-based healthcare system, analyzed the data for seasonal variations, and noted that a higher percentage of psoriasis patients were clear or almost clear in the summer than in the winter, with statistically significant variation in the percentage of patients who were clear or almost clear across the different seasons.  This outcome is biologically plausible, because UV (ultraviolet) light exposure is greater in the summer than in the winter, with the difference in exposure more marked at higher latitudes, and because UV exposure is known to ameliorate psoriasis.  However, the results from Pascoe and Kimball may be confounded by the concomitant treatments that the psoriasis patients were receiving at their office visits.  To eliminate the effect of this confounding, analysis of controlled clinical trial data would be valuable.
DOI: 10.25934/00004319
title: Clinical implications of body mass index and weight in metastatic breast cancer patients receiving abemaciclib. A combined individual patient level data sub-analysis of MONARCH 2 and MONARCH 3 trials.

description: Obesity, weight gain and body composition measures have received increasing attention as potential prognostic and predictors factors of toxicity in breast cancer (BC) patients, besides their well-known role as risk factors for the development of BC, particularly in the postmenopausal setting. A series of clinical trials have observed that excess weight in pre and postmenopausal BC patients is associated with higher recurrence rates and poorer survival compared to normal weight. This negative prognostic effect of obesity was additionally supported by several meta-analyses, being stronger for estrogen receptor-positive breast cancer. 

In the metastatic setting the prognostic relationship between body max index (BMI) and prognosis is still debatable, as results are contradictory. Recent findings in metastatic breast cancer differ with data from studies in early-stage BC, as they show that, paradoxically, obesity may be a potential protective factor in the metastatic setting. This favourable aspect of obesity appeared also in patients with metastatic solid tumours treated with immunotherapy.   Additional research is needed to clarify the complex relationship between BMI in metastatic BC to tailor weight management strategies after cancer diagnosis and hopefully improve overall clinical outcome.

There is strong pre-clinical data suggesting that cell cycle regulators (ex: cyclin-dependent kinase 4 and 6 [CDK 4/6]) also have an impact on cell metabolism and metabolic functions (adipose tissue, glucose regulation, and muscular tissue). Recent studies pointed CDK-4 and CDK-6 as potentials preclinical targets for diet-induced obesity, suggesting that these drugs could have more effect on body fat mass than on body muscle mass. 

Giving this potential relationship between obesity and CDK 4/6, this research project will assess if obesity can impact efficacy outcomes and toxicity profile in patients receiving CDK 4/6 inhibitors. We also aim to evaluate weight changes in patients under this treatment and its impact with clinical outcomes (in terms of progression free survival). The MONARCH 2 and MONARCH 3 are important prospective randomized studies evaluating the use of a CDK 4/6 inhibitor, abemaciclib, in hormonal positive metastatic BC. We intend to use data from these studies to test our hypothesis.
DOI: 10.15472/jquf92
title: Especies de arbolado urbano y sus medidas de captura y almacenamiento de carbono en la Medialuna Del Sur De Bogotá D.C. - Colombia

description: Este set de datos comprende los resultados obtenidos por cada especie evaluada (59 en total) dentro del marco del proyecto "Captura y almacenamiento de carbono en el arbolado urbano de la Medialuna Del Sur De Bogotá D.C. - Colombia", y contiene la estimación de la captura y almacenamiento de carbono en las localidades más vulnerables al cambio climático en la ciudad de Bogotá, se realizaron estimaciones de biomasa aérea, carbono almacenado y capturado anualmente y, CO2eq (CO2 equivalente) removido de la atmósfera por parte del arbolado urbano evaluado. Estas estimaciones fueron realizadas hasta el año 2022 y estuvieron basadas en mediciones parciales aleatorias de árboles y, en la base de datos fitosanitaria del censo del arbolado urbano SIGAU.
description: Se implementaron dos metodologías comparativas, la primera basada en el protocolo para la estimación nacional y subnacional de biomasa-Carbono en Colombia mediante el uso de ecuaciones alométricas basadas en las variables DAP, altura y densidad de madera. La segunda metodología incluye el procesamiento de la información en el software I-Tree ECO versión 6. En este set de datos se encontrarán los resultados obtenidos por cada metodología evaluada, incluyendo datos descriptivos como el número de árboles evaluados por cada especie, información taxonómica y de ubicación espacial. Por otro lado, podrá encontrar los resultados de las estimaciones de la captura anual de carbono y remoción anual de CO2eq, almacenamiento total de carbono y remoción total de CO2eq. De igual forma se encuentra el promedio de cada uno de estos por árbol de cada especie, todo esto según la metodología 1 y 2.
DOI: 10.25934/00004327
title: Analysis of Total Events and Hospitalizations in the SPARCL Study

description: Clinical benefit in endpoint-directed studies of cardiovascular (CV) disease is often characterized as an intervention reducing the risk of the first event in a composite of related non-fatal CV events and either all-cause or cause-specific death.  By design, additional events in the composite that may occur after a patient’s first non-fatal event are available for analysis, and patients are typically encouraged to remain on randomized therapy through the first reported non-fatal event due, in part, to uncertainty the initial event will qualify as first in the composite.  Consequently, the analysis of only the first event in the composite does not capture the entire impact of the interventional treatment on all documented events.

Several studies have demonstrated the benefits of intensive statin therapy on reducing first and subsequent non-fatal CV events in the settings of stable coronary heart disease (CHD) and post-acute coronary syndrome (ACS) (Tikkanen 2009; Murphy 2009; LaRosa 2010; Murphy 2016; Schwartz 2017), and similar findings have been reported with other interventional classes (White 2014).  In these settings, follow-up for total non-fatal events is frequently interrupted by a competing event of death.  Since it is anticipated that occurrences of non-fatal CV events will be associated with an increased risk of subsequent fatal events, deaths likely violate the non-informative censoring assumption for non-fatal events, regardless of whether all-cause or cause-specific deaths are included in the composite of total non-fatal and fatal events.  Additionally, the statistical methods used in these prior analyses do not account for and/or quantify the possible association between total non-fatal and fatal events.  Since these studies have not demonstrated consistent reductions in death associated with interventional therapy, it is not known if this could be explained by the nature of the association between non-fatal and fatal events within the study.  For example, there may be a weak association between non-fatal and fatal events within these trials, and therefore reducing the risk of total non-fatal events would not necessarily be expected to modify the risk of fatal events.

To overcome these limitations, a novel approach is proposed to jointly model total non-fatal and fatal events in a pre-specified analysis of the SPARCL trial, allowing for the possibility that patients may experience multiple related non-fatal events.  The method formally quantifies the association between non-fatal and fatal events while accounting for the fact that competing terminal events interrupt the non-fatal events process.

Note that no known analyses of total events in SPARCL have been completed to date.
DOI: 10.25934/00004540
title: Efficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial

description: Atrial fibrillation (AF) is common in older people, and is associated with an increased risk of both mortality and stroke.(1) Frailty is a condition in which there is a decline in biological reserves and deterioration in physiological mechanisms, which render the person vulnerable to a range of additional adverse outcomes.(2) Frailty provides an insight into biological age and is more useful than chronological age in predicting adverse events including death.(3) Frailty therefore provides a clinically useful framework in approaching individualised care planning, including the relative risks and benefits associated with a clinical intervention.

Patients with AF commonly have concomitant frailty.(3, 4) However, there is a lack of evidence to guide the management of AF in people who also have frailty.(1) Whilst there is evidence to support the use of Apixaban for stroke prophylaxis in AF for patients with multi-morbidity,(5) there are currently no studies that use a validated method of defining frailty in order to report clinical outcomes associated with direct oral anticoagulation for patients with AF by frailty category.(1, 6) It is therefore unknown whether the risks and benefits associated with anticoagulation differ by frailty category. We would like to investigate this question using data from the ENGAGE AF-TIMI 48 trial.
DOI: 10.7924/r43r1215n
title: Data from: Facile Mechanochemical Cycloreversion of Polymer Cross-linkers Enhances Tear Resistance

description: The mechanical properties of covalent polymer networks often arise from the permanent end-linking or cross-linking of polymer strands, and molecular linkers that break more easily would likely produce materials that require less energy to tear. We report that cyclobutane-based mechanophore cross-linkers that break via force-triggered cycloreversion lead to networks that are up to 9 times tougher than conventional analogs. The response is attributed to a combination of long, strong primary polymer strands and cross-linker scission forces that are ~ 5-fold smaller than control cross-linkers at the same timescales. The enhanced toughness comes without the hysteresis associated with noncovalent cross-linking, and it is observed in two different acrylate elastomers, in fatigue as well as constant displacement rate tension, and in a gel as well as elastomers.
DOI: 10.5517/ccdc.csd.cc2g5z5t
title: CSD 2269856: Experimental Crystal Structure Determination

description: Related Article: Andrey Shablinskii|2023|CSD Communication|||
description: An entry from the Inorganic Crystal Structure Database, the world’s repository for inorganic crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the joint CCDC and FIZ Karlsruhe Access Structures service and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.17909/z80p-1q97
title: Data used in M101 paper

description: Time-series HST WFC3/IR F110W and F160W observations of the field of SN 2011fe used in the search for Mira variables in giant spiral galaxy M101
DOI: 10.26093/cds/vizier.32750067
title: Velocity Field of the outer Galaxy

description: VizieR online Data Catalogue associated with article published in journal Astronomy & Astrophysics with title 'The Velocity Field of the outer Galaxy' (bibcode: 1993A&A...275...67B)
DOI: 10.26093/cds/vizier.35780128
title: VI light curves of NGC4590 variables

description: VizieR online Data Catalogue associated with article published in journal Astronomy & Astrophysics with title 'A census of variability in globular cluster M68 (NGC 4590).' (bibcode: 2015A&A...578A.128K)
DOI: 10.26093/cds/vizier.36090084
title: VIPERS spectroscopic redshifts (PDR-2)

description: VizieR online Data Catalogue associated with article published in journal Astronomy & Astrophysics with title 'The VIMOS Public Extragalactic Redshift Survey (VIPERS). Full spectroscopic data and auxiliary information release (PDR-2).' (bibcode: 2018A&A...609A..84S)
DOI: 10.18120/chha-kv70
title: Essential tremor during rest, move, posture
DOI: 10.26093/cds/vizier.36550114
title: HSC Variables in i-band

description: VizieR online Data Catalogue associated with article published in journal Astronomy & Astrophysics with title 'Strongly lensed candidates from the HSC transient survey.' (bibcode: 2021A&A...655A.114C)
DOI: 10.5066/p9625zb9
title: Velocity Survey at Cross Sections in the Illinois River below Starved Rock Lock and Dam near Utica, Illinois, June 16, 2021

description: In support of U.S. Geological Survey invasive carp research examining aggregations of invasive carp in the tail water of dams, water velocity measurements were made at cross sections in the Illinois River below Starved Rock Lock and Dam on June 16, 2021. A total of 16 cross sections were surveyed, with two transects per cross section. Water depth and crew safety limited the extent of the survey. The discharge in the Illinois River at Starved Rock Lock and Dam at the time of data collection was approximately 185.7 cubic meters per second. The data were processed in the Velocity Mapping Toolbox (VMT) v.4.09 (Parsons and others, 2013) to obtain a depth-averaged velocity field for each cross section from paired transects at each cross section. References Cited: Parsons, D.R., Jackson, P.R., Czuba, J.A., Engel, F.L., Rhoads, B.L., Oberg, K.A., Best, J.L., Mueller, D.S., Johnson, K.K. and Riley, J.D., 2013, Velocity Mapping Toolbox (VMT): a processing and visualization suite for moving-vessel ADCP measurements, Earth Surface Processes and Landforms, v. 38, no. 11, p. 1244?1260. [Also available at https://doi.org/10.1002/esp.3367].
DOI: 10.26093/cds/vizier.51650008
title: Mass Production 2021 KMTNet Microlensing Planets. III

description: VizieR online Data Catalogue associated with article published in journal Astronomical Journal (AAS) with title 'Mass Production of 2021 KMTNet Microlensing Planets. III. Analysis of Three Giant Planets.' (bibcode: 2023AJ....165....8S)
DOI: 10.26093/cds/vizier.19140130
title: Chandra & VLA obs. of 14 high-redshift QSOs

description: VizieR online Data Catalogue associated with article published in journal Astronomical Journal (AAS) with title 'Discovery of candidate X-ray jets in high-redshift quasars.' (bibcode: 2021ApJ...914..130S)
DOI: 10.26093/cds/vizier.19160081
title: Grus I and Indus II deep DES photometry

description: VizieR online Data Catalogue associated with article published in journal Astronomical Journal (AAS) with title 'A deeper look at DES dwarf galaxy candidates: Grus I and Indus II.' (bibcode: 2021ApJ...916...81C)
DOI: 10.26093/cds/vizier.19190049
title: SNIa SN2017fgc follow-up phot. & spectra

description: VizieR online Data Catalogue associated with article published in journal Astronomical Journal (AAS) with title 'SN 2017fgc: a fast-expanding type Ia supernova exploded in massive shell galaxy NGC 474.' (bibcode: 2021ApJ...919...49Z)